Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

A new study published in the Journal of American Medical Association showed that glucagon-like peptide-1 receptor agonists ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this ...

A small clinical trial in China suggests that a low-dose vitamin E supplement could improve liver tissues and scarring for ...

Researchers believe that Semaglutide shows promise in cutting the risk of conditions that could impair memory and thought ...

Weight-loss jabs and those for diabetes may be linked to a lower risk of dementia, a study suggests. Semaglutide in particular, whose brand names include Wegovy and Ozempic, showed promise in cutting ...

FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...

New Delhi: In line with the 'Not of Standard Quality' data provided by states, the apex drug regulatory body, the Central ...

1 College of Medicine and Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia 2 School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom Introduction: ...